Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
HA121-28 tablets
DRUG
3 trials
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
Advanced Solid Tumor
Biliary Tract Cancer
Medullary Thyroid Carcinoma
Phase 1
Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets
NCT03994484
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
Start: 2018-10-10
End: 2022-12-30
Target: 44
Updated: 2022-02-10
Phase 2
A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
Terminated
NCT04784520
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Biliary Tract Cancer
Start: 2021-06-22
End: 2022-12-28
Updated: 2023-02-06
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
NCT04787328
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Medullary Thyroid Carcinoma
Start: 2021-07-13
End: 2025-03-31
Target: 30
Updated: 2022-02-23
Related Papers
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.
2025-02-28